CCM
FHTX icon

CAAS Capital Management’s Foghorn Therapeutics FHTX Stock Holding History

CAAS Capital Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-15,000
Closed -$304K – 1236
2020
Q4 		$304K Buy
+15,000
New +$287K ﹤0.01% 726

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAAS Capital Management's FHTX Position: Q1 2021 in Review

CAAS Capital Management sold out of Foghorn Therapeutics (FHTX) in Q1 2021, closing a stake of 15,000 shares — an estimated $304K sold.

CAAS Capital Management first reported a position in FHTX in Q4 2020 and held it in 1 quarter. The position peaked at $304K in Q4 2020. 45 funds tracked by Wall St. Rank hold FHTX as of Q1 2021.

  • CAAS Capital Management reported no remaining Foghorn Therapeutics position as of Q1 2021 after selling out during the quarter.
  • CAAS Capital Management sold 15,000 Foghorn Therapeutics shares in Q1 2021, an estimated $304K.
  • CAAS Capital Management first reported a position in Foghorn Therapeutics in Q4 2020 and held it in 1 quarter.
  • CAAS Capital Management's Foghorn Therapeutics position peaked at $304K in Q4 2020.
  • 45 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2021.

Based on CAAS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.